ArticleDiscover oncology2025
Outcomes and prognostic markers in locally advanced head and neck squamous cell carcinoma underwent chemoradiotherapy.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHead and neck squamous cell carcinoma (HNSCC) has poor survival outcomes, particularly in locally advanced stages. Identifying prognostic factors can help personalize treatment and improve outcomes.
methodWe retrospectively analyzed stage III-IVA/B HNSCC patients who received definitive or adjuvant CRT from January 2015 to January 2024. Demographic, clinical, and laboratory data were collected.
resultsThe study included 138 patients. A total of 84 patients received CRT for the definitive aim, while 55 patients received it for the adjuvant aim. The median event free survival (EFS) was 7.65 years (95%CI 6.14-9.15). Factors associated with poor EFS in multivariate analysis were stage IVA/B disease (HR 2.58, 95%CI 1.21-5.49), being underweight (HR 3.54, 95%CI 1.57-7.96), and higher NLR (HR 2.51, 95%CI 1.30-4.85). Stage IVA/B disease were associated with poorer OS in multivariate analysis (HR 3.07, 95%CI 1.22-7.69). Male gender was associated with prolonged EFS and overall survival (HR 0.51, 95%CI 0.27-0.96 and HR 0.33, 95%CI 0.15-0.74, respectively).
conclusionIn conclusion, female gender, stage IVA/B disease, being underweight, and having a high NLR were independent predictors of EFS while female gender and stage IVA/B disease were independent predictors for OS in patients with HNSCC who were treated with CRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.